HC Wainwright & Co. Initiates Coverage On eFFECTOR Therapeutics with Buy Rating, Announces Price Target of $5
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has initiated coverage on eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy rating and a price target of $5.
August 24, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
eFFECTOR Therapeutics has been initiated with a Buy rating by HC Wainwright & Co. with a price target of $5.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $5 indicates a positive outlook for eFFECTOR Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100